We develop skeletal muscle-targeted LNPs through lipid modification and surface functionalization, providing end-to-end support from design and synthesis to formulation, characterization, and delivery evaluation.
Skeletal muscle-targeted LNPs are engineered to improve the delivery of nucleic acids to skeletal muscle tissue and muscle-associated cell populations. Unlike conventional LNPs that frequently accumulate in the liver, muscle-targeted formulations use tailored ionizable lipids, PEG-lipid architectures, or surface-displayed targeting ligands to modify tissue distribution and cellular uptake. These systems are being investigated for mRNA expression, gene silencing, genome editing, muscle regeneration, and metabolic disease research.
BOC Sciences provides integrated targeted LNP development, covering ionizable lipid screening, targeting ligand synthesis, surface functionalization, payload encapsulation, formulation optimization, and cellular and in vivo evaluation. We support the development of customized LNPs for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing research, with formulation strategies selected according to the intended muscle target and delivery route.
Skeletal Muscle-Targeted Lipid Nanoparticle IllustrationOur development services integrate lipid chemistry, surface engineering, nanoparticle formulation, and biological evaluation to address the challenges of skeletal muscle delivery. Projects can start with an existing LNP formulation, a specific targeting ligand, or a defined muscle-delivery objective. We customize the development scope according to payload properties, target-cell characteristics, and the intended administration route.
We investigate how ionizable lipid structures and supporting lipid components influence muscle-cell interactions, intracellular delivery, and tissue distribution.
We develop ligand-functionalized LNPs to improve interactions with selected muscle-associated cell populations. Ligand identity, attachment chemistry, surface orientation, and display density are evaluated together.
We integrate lipid composition, targeting modifications, and payload properties into a formulation strategy designed for the intended muscle-delivery application.
We evaluate the physicochemical properties of candidate LNPs alongside muscle-cell delivery and tissue-level performance to identify whether formulation improvements translate into functional payload delivery.
Skeletal muscle-targeted LNPs can be developed through intrinsic lipid engineering or surface functionalization with muscle-associated peptides, fusogens, and antibodies. BOC Sciences supports lipid design and synthesis, ligand modification, LNP formulation, and delivery evaluation. The following strategies provide different options for developing muscle-targeted delivery systems.
Muscle-selective LNPs can be developed by modifying ionizable lipid headgroups, hydrophobic tails, and linker structures to influence tissue distribution, membrane interactions, and endosomal escape. BOC Sciences supports customized ionizable lipid design, synthesis, structural screening, and LNP formulation.
Research reference: iso-A11B5C1-based muscle-selective mRNA-LNPs (PNAS, 2023); A chemically defined ionizable-lipid LNP platform for intramuscular mRNA and CRISPR delivery (Nature Communications, 2021).
Muscle-selective delivery can be explored by modifying PEG-lipid hydrophobic anchors and linkers, which influence LNP surface properties, membrane interactions, and tissue distribution. BOC Sciences supports PEG-lipid design, synthesis, and composition optimization for muscle-oriented formulations.
Research reference: Pr-182-BNT (P1B) LNPs containing branched, asymmetric-tail PEG-lipids for muscle-selective mRNA delivery (Small, 2026).
Muscle-associated peptides and fusogenic proteins can be displayed on LNP surfaces to enhance interactions with muscle-cell membranes or support fusion-related delivery. BOC Sciences supports peptide synthesis, protein-related surface engineering, lipid-anchor conjugation, and LNP functionalization.
Research reference: MyomP1-DSPE-PEG-functionalized LNPs for muscle-targeted gene delivery (Molecular Therapy – Nucleic Acids, 2026); Myomaker-functionalized LNPs for myogenic cell mRNA delivery (Advanced Functional Materials, 2026).
Antibody-functionalized LNPs use surface-displayed recognition components to interact with selected muscle-associated markers and promote target-cell association. BOC Sciences supports antibody selection, conjugation chemistry, surface orientation optimization, and functionalized LNP development.
Research reference: miR-130a-loaded LNPs displaying five modified muscle-associated receptor-recognition components (Journal of Nanobiotechnology, 2025).
Share your payload and target-cell requirements. BOC Sciences can help evaluate feasible design options, synthesize relevant components, and develop a comparative formulation strategy.
BOC Sciences develops muscle-targeted LNPs for the payload classes most frequently used in skeletal muscle delivery research. Each payload requires a matched loading strategy, particle design, and functional readout, and we help connect muscle-targeting design with payload-specific formulation requirements.
| Payload Type | Supported Uses & Muscle-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| Muscle-Targeted LNP for mRNA | Designed for reporter expression, protein replacement studies, and myotube-directed expression research. Development focuses on mRNA integrity, encapsulation efficiency, muscle-cell transfection, and muscle-versus-liver expression ratios, supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Muscle-Targeted LNP for siRNA | Suitable for gene-knockdown studies in myotube and myofiber-relevant models, including pathways involved in atrophy and metabolism. Development evaluates siRNA encapsulation, target silencing in muscle cells, and selectivity against hepatic uptake, drawing on our lipid nanoparticles for siRNA delivery experience. | Inquiry |
| Muscle-Targeted LNP for Cas9 mRNA and sgRNA | Applicable to genome-editing research in muscle models, where transient Cas9 expression and repeat-dosing capability are key advantages of LNP delivery. We evaluate co-loading of Cas9 mRNA and guide RNA, editing readouts in muscle cell models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities. | Inquiry |
| Muscle-Targeted LNP for circRNA and saRNA | Designed for payloads that require strong protection and sustained expression in muscle tissue. Development considers payload integrity, encapsulation behavior, particle stability, and expression duration in muscle-associated cell models, supported by our lipid nanoparticles for circRNA delivery platform. | Inquiry |
| Muscle-Targeted LNP for ASO | Suitable for splice-modifying and knockdown oligonucleotide research in muscle models, where oligonucleotide delivery to myofibers remains a major bottleneck. Development focuses on oligonucleotide loading, nuclear delivery, and uptake comparison across muscle cell populations, supported by our lipid nanoparticles for ASO delivery services. | Inquiry |
| Muscle-Targeted LNP for Protein and Peptide | Applicable to enzymes, signaling proteins, and peptide payloads intended for muscle-associated delivery research. Formulation work emphasizes mild loading conditions, aggregation control, and preserved biological activity, drawing on our protein encapsulation in LNPs experience. | Inquiry |
| Muscle-Targeted LNP for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules studied in muscle metabolism and atrophy research. We evaluate drug–lipid compatibility, loading method, retention during surface modification, and release behavior, supported by hydrophobic payload encapsulation in LNPs. | Inquiry |
| Muscle-Targeted LNP for Fluorescent and Tracking Labels | Supports labeled particles used to map muscle-associated uptake, intracellular localization, and in vivo distribution trends across muscle groups, enabled by our tracking-labeled lipid nanoparticles capabilities. | Inquiry |
| Muscle-Targeted LNP for Custom Payload | Developed for unusual payloads, co-delivery systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, muscle-targeting modification route, particle stability, and delivery performance in the agreed muscle cell models. | Inquiry |
Tell us your payload, target muscle group, and delivery goal, and BOC Sciences will propose a muscle-targeting strategy that fits your project.
Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective. We organize the work into four practical stages and refine the plan as formulation and biological evidence becomes available.

We review the payload class, target muscle group, intended cell population—mature myofibers, myoblasts, or satellite-cell-associated models—baseline LNP formulation if available, and desired biological readouts. These inputs define the starting materials, comparator models, and the screening plan.

We propose candidate ionizable lipids, helper lipid and cholesterol balances, and PEG-lipid architectures, then select the targeting layer—lipid-intrinsic selectivity, peptide or fusogen display, or antibody orientation. Ratios are optimized through structured LNP lipid ratio optimization services, and each design includes matched non-targeted control LNPs.

Candidates are prepared under controlled mixing conditions and compared for particle size, PDI, zeta potential, ligand density, and payload retention. During LNP process optimization, we adjust composition, ligand input, purification, and buffer exchange, then advance only candidates that meet agreed particle-attribute thresholds.

Selected candidates are evaluated in muscle cell models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression or gene knockdown. Combined nanoparticle cellular & in vivo evaluation then compares muscle-associated delivery against hepatic and splenic accumulation. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.
A muscle-targeted LNP may be well characterized chemically yet still deliver mostly to the liver or transfect muscle cells inefficiently. We investigate formulation and biological factors together and use matched comparison studies to identify the step limiting performance.
✔ Hepatic Accumulation and Off-Target Organ Exposure
ApoE adsorption and LDL receptor-mediated uptake draw conventional LNPs into the liver, leaving little payload for muscle tissue. We compare ionizable lipid structures, PEG-lipid densities, and helper lipid balances to shift biodistribution, and quantify the muscle-to-liver delivery ratio for every candidate rather than relying on total expression data.
✔ Limited Vascular Transport and Muscle Tissue Penetration
The continuous endothelium of muscle vasculature and the dense extracellular matrix around myofibers restrict particle access. We tune particle size, surface charge, and PEG architecture within ranges compatible with tissue penetration, and verify the effects directly using uptake and distribution measurements instead of assuming that smaller particles always deliver better.
✔ Uneven Distribution Across Muscle Groups and Target Cell Populations
Delivery can differ widely between muscle groups and between myofibers and satellite-cell-associated populations. We use labeled particles and compartment-aware readouts to map where payload expression actually occurs, then adjust ligand density, composition, and administration-compatible design variables to reduce variability across the intended cell populations.
✔ Ligand Accessibility, Formulation Stability, and Endosomal Escape
Surface ligands can be masked by PEG, destabilize the particle, or improve uptake without improving cytosolic payload availability. We measure ligand exposure alongside particle stability, compare intracellular localization with functional readouts, and apply LNP endosomal escape evaluation to identify post-uptake limitations before reformulating.
Tell us about your current lipid composition, targeting strategy, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused optimization plan.
Skeletal muscle-targeted LNPs offer opportunities for nucleic acid delivery in genetic muscle disorders, muscle wasting, metabolic dysfunction, and tissue repair. BOC Sciences supports customized LNP development for these applications, including payload selection, lipid and ligand engineering, formulation optimization, and functional delivery evaluation.
Tell us your intended application and development requirements. Drawing on our experience and relevant published research, BOC Sciences can help design, synthesize, formulate, and evaluate skeletal muscle-targeted LNPs tailored to your project.
We connect ionizable lipid structure, helper lipid balance, and PEG architecture to biodistribution outcomes, helping teams move beyond liver-tropic default formulations with a defined, data-supported design logic.

Our workflows cover myotropic lipid candidates, peptide and fusogen-derived ligands, cell-penetrating motifs, and antibody display, allowing the targeting layer to be matched to the payload and cell population rather than forced onto a fixed platform.
Particle profiling, muscle-cell uptake and functional readouts, and in vivo distribution studies are combined in one program, so that formulation changes can be interpreted against both cellular and tissue-level delivery data.
Screening campaigns are organized around parallel candidate comparison with agreed endpoints, giving teams fast, interpretable feedback on which design variable to adjust in the next iteration.
From ligand selection and lipid synthesis to formulation, characterization, and delivery evaluation, the full development chain is handled within one integrated plan, reducing the disconnect between targeting chemistry and particle performance.
Skeletal muscle-targeted LNPs are designed to improve nucleic acid delivery to skeletal muscle tissues and specific muscle-associated cell populations. Unlike conventional LNPs that often exhibit substantial hepatic accumulation, muscle-targeted systems use modified ionizable lipids, optimized PEG-lipid architectures, or surface-displayed targeting components to influence tissue distribution and cellular uptake. Their targeting performance depends on lipid composition, particle properties, administration route, and the biological characteristics of the intended muscle target.
Several approaches can be explored to improve skeletal muscle delivery. Ionizable lipid engineering modifies lipid headgroups and hydrophobic tails to influence tissue distribution and intracellular release. PEG-lipid structural optimization can alter particle interactions and muscle tropism. Surface functionalization with muscle-associated peptides, fusogenic proteins, or antibodies provides additional opportunities for cellular recognition. These approaches can be investigated individually or combined, depending on the target cell population, payload, and intended administration route.
Skeletal muscle-targeted LNPs can be developed for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing components such as Cas9 mRNA and guide RNA. Potential applications include protein expression, gene silencing, genetic modification, and regulation of muscle-associated metabolic pathways. Other payloads, including antisense oligonucleotides, proteins, and selected small molecules, can also be explored. The appropriate formulation depends on payload structure, loading requirements, intracellular delivery mechanisms, and the intended biological readout.
Evaluation generally combines physicochemical characterization, cellular uptake studies, functional payload assessment, and tissue-level distribution analysis. Particle size, PDI, zeta potential, morphology, encapsulation efficiency, and payload integrity are examined first. Cellular studies can compare uptake and functional delivery in myoblasts, differentiating myocytes, and myotubes. Where appropriate, studies investigate muscle accumulation, distribution across different muscle groups, target-cell localization, and off-target organ exposure. Results are interpreted together to distinguish particle accumulation from productive payload delivery.
Yes. BOC Sciences provides customized skeletal muscle-targeted LNP development, covering ionizable lipid design and synthesis, PEG-lipid optimization, targeting peptide or antibody functionalization, payload encapsulation, and formulation development. We can also support physicochemical characterization, muscle-cell uptake studies, functional delivery assessment, and distribution evaluation. Based on your intended application, target muscle, payload, and administration route, our team can help select suitable design strategies and establish a project-specific development and evaluation plan.